- Home
- DYN
as 05-20-2024 4:00pm EST
$.
+$.
+.%
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.4B | IPO Year: | 2020 |
| Target Price: | $39.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.40 - $35.31 | Next Earning Date: | 05-02-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Farwell Wildon | DYN | Chief Medical Officer | Mar 11 '24 | Sell | $25.70 | 1,585 | $40,734.50 | 151,590 | SEC Form 4 |
| Farwell Wildon | DYN | Chief Medical Officer | Mar 11 '24 | Sell | $25.58 | 1,030 | $26,347.40 | 150,560 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Mar 8 '24 | Sell | $26.66 | 26,908 | $717,367.28 | 159,383 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Mar 8 '24 | Sell | $27.41 | 291 | $7,976.31 | 159,092 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Mar 8 '24 | Sell | $25.70 | 2,292 | $58,904.40 | 156,800 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 8 '24 | Sell | $25.31 | 30,755 | $778,409.05 | 177,452 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 8 '24 | Sell | $26.72 | 55,208 | $1,475,157.76 | 122,244 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 8 '24 | Sell | $27.33 | 289 | $7,898.37 | 121,955 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 8 '24 | Sell | $25.70 | 1,082 | $27,807.40 | 120,873 | SEC Form 4 |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Mar 8 '24 | Sell | $24.99 | 1,590 | $39,734.10 | 119,283 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | Mar 8 '24 | Sell | $25.46 | 34,663 | $882,519.98 | 196,521 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | Mar 8 '24 | Sell | $26.72 | 54,648 | $1,460,194.56 | 141,873 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | Mar 8 '24 | Sell | $27.31 | 689 | $18,816.59 | 141,184 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | Mar 8 '24 | Sell | $25.48 | 17,825 | $454,181.00 | 141,184 | SEC Form 4 |
| McNeill Jonathan | DYN | Chief Business Officer | Mar 8 '24 | Sell | $25.71 | 1,776 | $45,660.96 | 139,408 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 8 '24 | Sell | $25.30 | 202,238 | $5,116,621.40 | 715,490 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 8 '24 | Sell | $26.72 | 160,670 | $4,293,102.40 | 554,820 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 8 '24 | Sell | $27.38 | 435 | $11,910.30 | 554,385 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 8 '24 | Sell | $25.42 | 40,072 | $1,018,630.24 | 564,313 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 8 '24 | Sell | $26.10 | 9,928 | $259,120.80 | 554,385 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 8 '24 | Sell | $26.12 | 7,769 | $202,926.28 | 546,616 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 8 '24 | Sell | $25.93 | 8,618 | $223,464.74 | 537,998 | SEC Form 4 |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Mar 7 '24 | Sell | $25.85 | 2,373 | $61,342.05 | 154,433 | SEC Form 4 |
| HIGH SUSANNA GATTI | DYN | Chief Operating Officer | Mar 7 '24 | Sell | $25.85 | 1,591 | $41,127.35 | 186,291 | SEC Form 4 |
| Brumm Joshua T | DYN | CEO & President | Mar 7 '24 | Sell | $25.85 | 9,086 | $234,873.10 | 554,385 | SEC Form 4 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
MT Newswires
an hour ago
Dyne Therapeutics Launches $300 Million Share Offering
Investor's Business Daily
2 hours ago
Why Dyne Therapeutics, With A 166% Run This Year, Just Catapulted Again
GlobeNewswire
2 hours ago
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
MT Newswires
6 hours ago
Update: Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles
MT Newswires
8 hours ago
HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating
MT Newswires
8 hours ago
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
BioPharma Dive
10 hours ago
Dyne shares jump on trial data for muscle disease drugs
MT Newswires
10 hours ago